These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14998863)

  • 1. Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
    Todeschini G; Gelio S; Tecchio C
    Ann Oncol; 2004 Mar; 15(3):538-9. PubMed ID: 14998863
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
    Bernardi D; Giacalone A; Spina M; Tirelli U
    Ann Oncol; 2004 Aug; 15(8):1298. PubMed ID: 15277275
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
    Tomita N; Kodama F; Oshima R; Hashimoto C; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Sakai R; Fujita H; Fujisawa S; Kanamori H; Motomura S; Ishigatsubo Y
    Leuk Lymphoma; 2006 Jun; 47(6):1041-7. PubMed ID: 16840195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma.
    Zwick C; Gleissner B; Pfreundschuh M
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S43-9. PubMed ID: 18284715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P
    J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive lymphoma: improving treatment outcome with rituximab.
    Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for improving outcomes with 14-day anthracycline-based regimens in patients with aggressive lymphomas.
    Broussais-Guillaumot F; Coiffier B
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S50-6. PubMed ID: 18284716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.
    Osby E; Hagberg H; Kvaløy S; Teerenhovi L; Anderson H; Cavallin-Stahl E; Holte H; Myhre J; Pertovaara H; Björkholm M;
    Blood; 2003 May; 101(10):3840-8. PubMed ID: 12531794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravascular lymphoma presenting with cauda equina syndrome: treated with CHOP and rituxan.
    Davis TS
    Leuk Lymphoma; 2003 May; 44(5):887-8. PubMed ID: 12802932
    [No Abstract]   [Full Text] [Related]  

  • 11. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Alliot C
    J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
    [No Abstract]   [Full Text] [Related]  

  • 12. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
    Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
    Arcaini L; Orlandi E; Scotti M; Brusamolino E; Passamonti F; Burcheri S; Colombo N; Vanelli L; Sbalzarini G; Lazzarino M
    Clin Lymphoma; 2004 Mar; 4(4):250-2. PubMed ID: 15072617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):18-22. PubMed ID: 12040530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
    Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
    Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Tumori; 2002; 88(1 Suppl 1):S26-8. PubMed ID: 11989916
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
    Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.